慢性阻塞性肺疾病合并肌少症的研究新进展

doi:10.16138/j.1673-6087.2025.05.13

摘要/Abstract

摘要：

慢性阻塞性肺疾病（chronic obstructive pulmonary disease, COPD）是一种常见的慢性呼吸系统疾病，具有较高的致残率和致死率。肌少症是COPD患者一项重要的肺外表现，其发病率并不低。COPD合并肌少症的发病机制复杂，涉及氧化应激、全身炎症反应、细胞自噬、营养不良、活动减少等多种因素。目前研究发现，通过运动干预、营养支持和药物治疗，可提高患者肌肉力量和躯体功能，从而改善患者预后。本文对COPD合并肌少症的发病机制及治疗方法进行综述，以期为疾病研究及诊治提供参考。

关键词: 慢性阻塞性肺疾病, 肌少症, 发病机制, 流行病学

Abstract:

Chronic obstructive pulmonary disease (COPD) is one of the most common chronic diseases of the respiratory tract, with a high mortality and disability rate. Sarcopenia is an important extrapulmonary manifestation in COPD patients, and its incidence rate is not low. The pathogenesis of COPD complicated with sarcopenia involves oxidative stress, systemic inflammatory response, autophagy, malnutrition and decreased physical activity, etc. Current research has shown that exercise intervention, nutritional support, and medication treatment can improve patients’ muscle strength and physical mobility, thereby enhancing patient prognosis. This article comprehensively reviews the pathogenesis and treatment of COPD complicated with sarcopenia, aiming to provide a valuable reference for disease research, diagnosis and treatment.

Key words: Chronic obstructive pulmonary disease, Sarcopenia, Pathogenesis, Epidemiology

中图分类号:

R563

王怡, 黄辉. 慢性阻塞性肺疾病合并肌少症的研究新进展[J]. 内科理论与实践, 2025, 20(05): 415-419.

WANG Yi, HUANG Hui. Advances in pathogenesis and treatment of chronic obstructive pulmonary disease complicated with sarcopenia[J]. Journal of Internal Medicine Concepts & Practice, 2025, 20(05): 415-419.

参考文献 33

[1]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版)[J]. 中华结核和呼吸杂志, 2021, 44(3): 170-205.
	Chinese Thoracic Society Chronic Obstructive Pulmonary Disease Group, Chinese Association of Chest Physicians Chronic Obstructive Pulmonary Disease Working Committee. Guidelines for diagnosis and treatment of chronic obstructive pulmonary disease (2021)[J]. Chin J Tuberc Respir Dis, 2021, 44(3): 170-205.
[2]	刘海霞, 周萍, 张一娜. 肌少症的诊断与治疗[J]. 中华骨质疏松和骨矿盐疾病杂志, 2021, 14(4): 434-440.
	Liu HX, Zhou P, Zhang YN. Diagnosis and treatment of sarcopenia[J]. Chin J Osteoporos Bone Miner Res, 2021, 14(4): 434-440.
[3]	赵雅洁, 何清, 徐志红. 肌少症对老年慢性阻塞性肺疾病患者生活质量及活动能力的影响[J]. 内科理论与实践, 2023, 18(6): 383-387.
	Zhao YJ, He Q, Xu ZH. Impact of sarcopenia on quality of life and mobility in elderly patients with chronic obstructive pulmonary disease[J]. J Intern Med Concepts Pract, 2023, 18(6): 383-387.
[4]	Yu Z, He J, Chen Y, et al. Chronic obstructive pulmonary disease as a risk factor for sarcopenia: a systematic review and meta - analysis[J]. PLoS One, 2024, 19(4): e0300730. doi: 10.1371/journal.pone.0300730
[5]	Sepúlveda-Loyola W, Osadnik C, Phu S, et al. Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and meta-analysis[J]. J Cachexia Sarcopenia Muscle, 2020, 11(5): 1164-1176. doi: 10.1002/jcsm.12600
[6]	Attaway AH, Lopez R, Welch N, et al. Muscle loss phenotype in COPD is associated with adverse outcomes in the UK Biobank[J]. BMC Pulm Med, 2024, 24(1): 186. doi: 10.1186/s12890-024-02999-7
[7]	黄祺, 韩乐乐, 凌玲, 等. 慢性阻塞性肺疾病合并肌少症的机制探讨[J]. 中华老年医学杂志, 2020, 39(8): 981-984.
	Huang Q, Han LL, Ling L, et al. Mechanisms linking chronic obstructive pulmonary disease and sarcopenia[J]. Chin J Geriatr, 2020, 39(8): 981-984.
[8]	齐苗, 江钟立. 老年人呼吸肌少症及其呼吸失能的评估和干预策略[J]. 中华老年医学杂志, 2023, 42(5): 592-597.
	Qi M, Jiang ZL. The assessment and intervention strategies of respiratory sarcopenia and sarcopenic respiratory disability in the elderly[J]. Chin J Geriatr, 2023, 42(5): 592-597.
[9]	Conejeros-Lillo S, Aguirre F, Cabrera D, et al. Role of the ubiquitin-proteasome system in the sarcopenic-like phenotype induced by CCL5/RANTES[J]. Eur J Transl Myol, 2024, 34(1): 12249.
[10]	Casati M, Costa AS, Capitanio D, et al. The biological foundations of sarcopenia: established and promising markers[J]. Front Med (Lausanne), 2019, 6: 184.
[11]	张兴宇, 郭琪, 陈小雨. 晚期糖基化终末产物在肌少症发病机制中的作用研究进展[J]. 中国医学科学院学报, 2024, 46(1): 111-118.
	Zhang XY, Guo Q, Chen XY. Research progress in the role of advanced glycation end products in the pathogenesis of sarcopenia[J]. Acta Acad Med Sin, 2024, 46(1): 111-118.
[12]	Pothier K, Gana W, Bailly N, et al. Associations between frailty and inflammation, physical, and psycho - social health in older adults: a systematic review[J]. Front Psychol, 2022, 13: 805501. doi: 10.3389/fpsyg.2022.805501
[13]	Xie G, Jin H, Mikhail H, et al. Autophagy in sarcopenia: possible mechanisms and novel therapies[J]. Biomed Pharmacother, 2023, 165: 115147. doi: 10.1016/j.biopha.2023.115147
[14]	Castets P, Rüegg MA. MTORC1 determines autophagy through ULK1 regulation in skeletal muscle[J]. Autophagy, 2013, 9(9): 1435-7. doi: 10.4161/auto.25722
[15]	胡丽, 赵旭, 黄小明. 老年慢性阻塞性肺疾病患者营养状况及其与少肌症的相关性[J]. 国际老年医学杂志, 2021, 42(1): 31-35.
	Hu L, Zhao X, Huang XM. Nutritional status of older patients with chronic obstructive pulmonary disease and the correlation with sarcopenia[J]. Int J Geriatr, 2021, 42(1): 31-35.
[16]	Di Donato M, Moretti A, Sorrentino C, et al. Filamin A cooperates with the androgen receptor in preventing skeletal muscle senescence[J]. Cell Death Discov, 2023, 9(1): 437. doi: 10.1038/s41420-023-01737-y
[17]	姚德志, 许衍硕, 谢亦欢. 慢性阻塞性肺疾病患者血清脂联素与营养状况、炎症因子的相关性[J]. 临床肺科杂志, 20156): 1034-1036.
	Yao DZ, Xu YS, Xie YH. Relationship of serum adiponectin to nutritional status and inflammation factors of COPD patients[J]. J Clin Pulm Med, 20156): 1034-1036.
[18]	Ma K, Huang F, Qiao R, et al. Pathogenesis of sarcopenia in chronic obstructive pulmonary disease[J]. Front Physiol, 2022, 13: 850964. doi: 10.3389/fphys.2022.850964
[19]	王一涵,张勤.老年人肌少症运动干预的研究进展[J].中国临床保健杂志,2024,27(2):187-191.
[20]	赵莹楚, 王小蕊, 葛政卿. 阶段性功能锻炼与抗阻运动对老年肌少症患者躯体功能和日常生活能力影响的对比[J]. 中国老年学杂志, 2022, 42(8): 1875-1878.
	Zhao YC, Wang XR, Ge ZQ. Comparison between effects of periodic functional exercise and resistance exercise on physical function and activities of daily living in elderly patients with sarcopenia[J]. Chinese Journal of Gerontology, 2022, 42(8): 1875-1878.
[21]	Marotta N, Demeco A, Moggio L, et al. Comparative effectiveness of breathing exercises in patients with chronic obstructive pulmonary disease[J]. Complement Ther Clin Pract, 2020, 41: 101260. doi: 10.1016/j.ctcp.2020.101260
[22]	夏金根, 巴文天. 慢性阻塞性肺疾病膈肌功能障碍和呼吸肌训练[J]. 中华结核和呼吸杂志, 2021, 44(9): 775-778.
	Xia JY, Ba WT. Diaphragm dysfunction and respiratory muscle training in patients with chronic obstructive pulmonary disease[J]. Chin J Tubere Respir Dis, 2021, 44(9): 775-778.
[23]	Kim SH, Shin MJ, Shin YB, et al. Sarcopenia associated with chronic obstructive pulmonary disease[J]. J Bone Metab, 2019, 26(2): 65-74. doi: 10.11005/jbm.2019.26.2.65
[24]	Kaltsakas G, Chynkiamis N, Anastasopoulos N, et al. Interval versus constant - load exercise training in adults with Cystic Fibrosis[J]. Respir Physiol Neurobiol, 2021, 288: 103643. doi: 10.1016/j.resp.2021.103643
[25]	罗君亭, 郭慧明, 郭敏, 等. 抗阻训练联合电刺激对老年性肌少症患者运动能力及生活质量影响的研究[J]. 江西医药, 2020, 55(8): 1005-1007.
	Luo JT, Guo HM, Guo M, et al. Effects of resistance training combined with electrical stimulation on exercise capacity and quality of life in patients with senile sarcoma[J]. Jiangxi Medical Journal, 2020, 55(8): 1005-1007.
[26]	杜舒婷, 邢彬, 朱磊, 等. 家庭神经肌肉电刺激对慢性阻塞性肺疾病患者肺功能、运动耐力及呼吸困难症状的影响[J]. 中华物理医学与康复杂志, 2021, 43(2): 144-146.
	Du ST, Xing B, Zhu L, et al. Effect of home-based neuromuscular electrical stimulation on pulmonary function, exercise tolerance, and dyspnea symptoms in COPD patients[J]. Chin J Phys Med Rehabil, 2021, 43(2): 144-146.
[27]	周衍香, 梅波, 徐峰, 等. 乳清蛋白对稳定期慢性阻塞性肺疾病合并肌少症患者呼吸肌力及肺功能的影响[J]. 山西医药杂志, 2022, 51(2): 182-185.
	Zhou YX, Mei B, Xu F, et al. Effect of whey protein on respiratory muscle strength and pulmonary function in patients with stable COPD complicated by sarcopenia[J]. Shanxi Med J, 2022, 51(2): 182-185.
[28]	Camargo CA Jr, Toop L, Sluyter J, et al. Effect of monthly vitamin D supplementation on preventing exacerbations of asthma or chronic obstructive pulmonary disease in older adults: post hoc analysis of a randomized controlled trial[J]. Nutrients, 2021, 13(2): 521. doi: 10.3390/nu13020521
[29]	Morimoto M, Yamaoka M, Hara T. A selective androgen receptor modulator SARM - 2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys[J]. Pharmacol Res Perspect, 2020, 8(1): e00563. doi: 10.1002/prp2.563
[30]	董蕙, 李芸, 邵发林. 生长激素、雄激素联合治疗COPD并发肌肉萎缩的研究[J]. 当代临床医刊, 2023, 36(5): 6-7.
	Dong H, Li Y, Shao FL. Combined therapy with growth hormone and androgen in patients with COPD and muscle atrophy[J]. the Medical Journal of Industrial Enterprise, 2023, 36(5): 6-7.
[31]	Polkey MI, Praestgaard J, Berwick A, et al. Activin type II receptor blockade for treatment of muscle depletion in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2019, 199(3): 313-320. doi: 10.1164/rccm.201802-0286OC
[32]	Liu C, Li L, Ge M, et al. MiR - 29ab1 cluster resists muscle atrophy through inhibiting MuRF1[J]. DNA Cell Biol, 2021, 40(9): 1167-1176. doi: 10.1089/dna.2021.0267
[33]	Lee EJ, Ahmad SS, Lim JH, et al. Interaction of fibromodulin and myostatin to regulate skeletal muscle aging: an opposite regulation in muscle aging, diabetes, and intracellular lipid accumulation[J]. Cells, 2021, 10(8): 2083. doi: 10.3390/cells10082083